Group a streptococcal antigens cross-reactive with myocardium. Purification of heart-reactive antibody and isolation and characterization of the streptococcal antigen by Van De Rijn, I et al.
GROUP A  STREPTOCOCCAL  ANTIGENS  CROSS-REACTIVE 
WITH  MYOCARDIUM 
Purification of Heart-Reactive Antibody and 
Isolation and Characterization 
of the Streptococcal Antigen* 
BY I.  vA~ Dz RIJN$, J.  B.  ZABRISKIE,  AND M.  McCARTY 
(From the Rockefeller University, New York, New York 10021) 
It is now well established that when experimental animals such as  the  rabbit are 
inoculated with group A streptococci, an antibody appears which binds to heart tissue (1- 
3).  This heart-reactive antibody (HRA)  1 will also bind to skeletal muscle and smooth 
muscle of vessel walls as well as preparations of sarcolemmal sheath of cardiac myofibers. 
HRAs have also been described in the sera of patients with acute rheumatic fever 
(ARF)  (4,  5).  Recently, it has been demonstrated that both group A  streptococcal cell 
walls (6)  and membranes (7)  can absorb these  antibodies from the sera.  HRA is also 
present in the sera of patients with postpericardiotomy syndrome (8, 9), Chagas' disease 
(10),  and Dressler's syndrome (11) as well as at the time of cardiac transplant rejection 
(12).  Streptococcal components, however, do not remove the HRA from sera of patients 
with this latter group of disorders. 
The antibodies to heart tissues in the patients with ARF and the detection of deposits of 
immunoglobulin  and complement in the myocardium of patients with rheumatic carditis 
(13) suggests a  possible autoimmune pathogenesis  (14).  This antibody occurs in these 
patients at  a  level  fourfold greater  than that  observed  in the  sera  of patients with 
uncomplicated streptococcal infections (5) and remains in the sera at elevated titers for a 
period of 3-5 yr after an acute attack. 
A number of attempts have been made by investigators to look further at the strepto- 
coccal antigen(s) responsible for this cross-reaction by using hydrolytic methods such as 
heating to 100°C at pH 2 or pepsin digestion (3, 7). By using his isolated antigen, Kaplan 
(3) could absorb HRA from the sera of rabbits inoculated with group A streptococci. By 
means of fluorescent absorption studies, he defined two cross-reactive systems in the cell 
wall of the streptococci.  One was serotype specific while the other was universal to all 
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group A streptococci tested (6,  15). The antigen preparation was not well characterized 
other than that it was sensitive to proteolytic enzymes and that it co-purified with type- 
specific M protein. 
Lyampert et al.  (16) and Danilova (17) also described a  type-specific cross-reactive 
antigen (CRA) in the cell wall of the group A streptococcus. These antigens cross-reacted 
only with cardiac myofibers. On the other hand, Zabriskie and Freimer (7) described a 
CRA which was present in all group A streptococcal membranes. HRA produced against 
these membranes bound to the sarcolemma of cardiac myofibers and also skeletal muscle 
and smooth  muscle cells of blood vessels.  They also demonstrated the  presence of a 
similar antigen in some group C and G streptococci. Nakhla and Glynn (18) demonstrated 
an antigen in groups A and G streptococci which cross-reacted with cardiac and skeletal 
tissue. They were able to detect this antigen in an M-negative mutant as did Zabriskie 
and Freimer (7). 
In this report, we present the partial purification from the group A streptococ- 
cal membrane of the antigen that cross-reacts with heart. In the course of these 
studies, it was found that HRAs in antisera of rabbits immunized with group A 
streptococci differ from those in sera of ARF patients. Neither will inhibit the 
binding of the other to the sarcolemma of cardiac myofibers, indicating that the 
antibodies  are  directed  to  different  antigenic  determinants.  Accordingly,  it 
proved necessary to purify and characterize HRAs from ARF sera to provide a 
reagent  suitable for  monitoring the  purification of the  relevant streptococcal 
membrane  antigen. 
Materials  and  Methods 
Cultures.  Streptococcal strains were obtained from the collection of Dr. R. C. Lancefield of our 
laboratory and were passed monthly through normal human blood.  The two group A type 6 
streptococcal  strains $43/19212 (mouse passed) and D471 (non-mouse passed) were both originally 
human isolates. 
All organisms were grown in dialyzed Todd-Hewitt broth (Difco Laboratories, Detroit, Mich.) 
prepared as follows: Todd-Hewitt (1,800 g) and yeast extract (Difco Laboratories) (180 g) were 
suspended in 1 liter of distilled water by heating at  100°C. Antifoam (Dow Corning Corp., 
Midland, Mich.) was added to prevent excessive foaming. The solubilized  media was then placed in 
dialysis tubing (Fisher Scientific Co.,  Pittsburgh, Pa.) and dialyzed against two changes of 30 
liters distilled water. The dialysate was finally sterilized by filtration into a Biogen Fermentor 
(American Sterilizer Co., New York) through a 0.22-~m Millipore Filter (MiUipore Corp., Bedford, 
Mass.). The Biogen Fermenter was then inoculated with 1.5 liters of a culture in the logarithmic 
phase of growth. When the pH of  the culture fluid  dropped to 7, 2 liters of 50% glucose was added, and 
the pH was kept constant at 7 by the addition of 5 N sodium hydroxide by using a Radiometer model 
11 titrater (Radiometer Corp., Copenhagen, Denmark). Cultures were harvested by using a Sharples 
high speed centrifuge (Sharpies-Stokes  Div., Pennwalt Corp., Warminster, Pa.) and frozen at -70°C 
until processed further. 
Preparation of Streptococcal Membrane 
GROUP A--PROTOPLAST  M~-MBRANE.  Phage-associated lysin was prepared and purified through 
the cellulose phosphate chromatography according to the procedure of Fischetti et al. (19). Group 
A streptococcal membranes were prepared by using the purified group C phage-associated lysin as 
described by Zabriskie and Freimer (7). After thawing, the organisms (120 g wet weight)  were 
washed with saline and resuspended in 1,200 ml of 0.06 M sodium phosphate  buffer (pH 6.1) 
containing  4% sodium chloride and 5 × 10  -4 M dithiothreitol (DTT). To this was added 1.2 × l0  s U 
of DTT-reactivated lysin and 5 mg of deoxyribonuclease (DNase) (Sigma Chemical Co., St. Louis, 
Mo.). The mixture was incubated at 37°C for 2 h and monitored for complete protoplast formation. 
After what appeared to be  100% conversion of streptococci  to protoplasts, the suspension was 
incubated for an additional I h. The protoplasts were then lysed in hypotonic buffer in the presence I.  van de  RIJN,  J.  B.  ZABRISKIE,  AND  M.  McCARTY  581 
of ribonuclease  (1.5  Kunitz  U/ml)  (RNase)  (Sigma  Chemical  Co.)  and  deoxyribonuclease  (36 
Kunitz U/m[) (DNase) (Sigma Chemical Co.).  After the cytoplasmic constituents were removed, 
the protoplast membranes were retreated with the enzymes followed by extensive washes with 
0.01  M  phosphate-buffered saline pH 7.6 (PBS). The remainder of the treatment and procedures 
followed those of Zabriskie and Freimer (7) by using 1,200 ml for all volumes. The final protoplast 
membrane preparations were lyophilized, the final yield usually being approximately 3 g. 
GROUP V M~.~mRANE.  Group D  membranes were prepared by glass bead disintegration in a 
Vibrogen cell mill (Rho Scientific, Commack, N. Y.) according to the procedure of Bleiweis et al. 
(20) with the modification of van de Rijn et al.  (21). 
All membrane preparations used in these studies were assayed for contaminating cell walls by 
using rhamnose as the marker sugar, and only those preparations with less than 0.1% contamina- 
tion were used in these studies (22). 
Preparation of Human Hea "~. Sarcolemmal Sheaths.  Fresh heart tissues (10 g) were homoge- 
nized in a Sorvall Omnimixer (DuPont Instruments, Sorvall Operations, Newtown, Conn.) in 0.05 
M CaC12 for 5 rain at 4°C. The thick slurry was centrifuged at 14,000 g  for 30 rain, and the pellet 
containing the sarcolemmal sheaths was then washed three times in saline.  The sarcolemmal 
sheaths were then allowed to autolyse in a 100-fold (vol/wt) excess of distilled water for 24 h at 4°C. 
The sheaths were sedimented at 14,000 g for 30 rain, and the process was repeated three times. The 
isolated sheaths were then treated with  DNase  and RNase  at  370C for 3  h  and  subsequently 
washed three times with distilled water and lyophilized. Under light microscopy, very few Z bands 
remained, indicating the loss of intracellular contents (23). This sarcolemmal sheath preparation 
served as the source of the insoluble antigenic matrix. 
Enzymatic Digestion 
TRYPSIN.  (bovine pancreas type  3,  Sigma  Chemical  Co.).  Membranes  (1  mg/ml)  were  sus- 
pended in 0.067 M phosphate buffer (pH 7.5) and incubated at 37°C for 1 h with trypsin (100; 1,000; 
or 10,000 U/ml). The reaction was stopped by adding twofold excess of soybean trypsin inhibitor 
(Sigma Chemical Co.). 
PEPSIN.  (hog stomach mucosa,  Sigma Chemical Co.).  Membranes (1 mg/ml) were suspended 
in 0.01  M  glycine-HC1 buffer (pH 2.2) and incubated at 37°C for 1 h  with pepsin  (100;  1,000;  or 
10,000 U/ml). The reaction was stopped by neutralizing the reaction mixture with 0.1 N  sodium 
hydroxide to pH 8.0. 
PAPAXN.  (papaya latex, Sigma Chemical Co.). Membranes (1 mg/ml) were suspended in 0.1 M 
sodium phosphate buffer pH 7.0 with 0.01 M cysteine and 0.001 M EDTA and incubated at 37°C for 
1  h  with  papain  (10,  20,  or  40  U/ml).  The  reaction  mixture  was  stopped  with  0.06  mg/ml 
iodoacetamide (Sigma Chemical Co.). 
PHOSPHOLXPASE-C.  (CL perfringens, Worthington Biochemical Corp., Freehold,  N. J.).  Mem- 
branes (1 mg/ml) were suspended in 0.1 M sodium phosphate buffer with 0.01 M calcium chloride 
(pH 7.3)  and incubated for i  h  at 37°C  with phospholipase C  (5,  25,  or 50 U). The reaction was 
stopped with 10 ml of 0.5 M  EDTA  (pH 7.0). 
ALPHA-aLVCOSID~SE.  (Saccharomyces cerevesiae,  Sigma Chemical Co.).  Membranes (1 mg/ml) 
were suspended in 0.05 M  sodium phosphate (pH 6.8) and incubated at 37°C  for 1 h  with alpha- 
glucosidase (5, 50, or 100 U/ml). 
BETA-OLUCOSmASE.  (Almonds, Sigma Chemical Co.). Membranes (1 mg/ml) were suspended in 
0.05 M sodium acetate buffer (pH 5.0) and incubated at 37°C for 1 h with beta-glucosidase (1 or 25 
U/ml). 
BETA-GALACTOSmASB.  (Escherichia coli, Worthington Biochemical Corp.).  Membranes (1 rag/ 
ml) were suspended in 0.1 M sodium phosphate buffer (pH 7.0) and incubated at 37°C for 1 h with 
beta-galactosidase (10,  100, or 1,000 U/ml). 
MIXED GLYCOSIDASES.  (minimum  12 glycosidic enzymes,  Miles Laboratories  Inc.,  Miles Re- 
search Products,  Elkhart, Ind.).  Membranes (1 mg/ml) were suspended in either 0.05 M  sodium 
acetate buffer (pH 5.0) or 0.05 M sodium acetate buffer (pH 6.0) and incubated at 37°C for 18 h with 
mixed glycosidases (0.2%). 
After the above enzymatic digestions were terminated, the residues were removed by centrifu- 
gation at 125,000  g  for 2 h  at 4°C.  The residues were washed two times with PBS (pH 7.6) and 
brought to their original volume.  The supernate was dialyzed extensively against PBS.  These 
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Lipid Extraction  and Fractionation 
METHOD I.  Membranes  (500  mg)  were  suspended  in  10 vol  (wt/vol) of chloroform/absolute 
methanol (2  to  1)  (vol/vol) as  determined by Folch et  al.  (24)  for the extraction of lipids.  The 
membranes were stirred at 4°C for 15 min. The suspension was then filtered in a  Buchner funnel 
under vacuum  (no.  576  filter paper,  Schleicher and SchueU),  and the extraction procedure was 
repeated two times. The filtrates were pooled and treated with 0.2 vol of calcium chloride (0.04%). 
The mixture was shaken vigorously and then allowed to separate into two layers. The upper layer 
was removed by aspiration, and the two layers were blown dry under nitrogen. The lipids from the 
lower layer  were  resuspended  in a  mixture of chloroform/methanol/water (60:30:4.5),  and any 
other nonlipid contaminants were removed by Sephadex chromatography according to the proce- 
dure of Wells and Dittmer (25).  After the sample was  loaded onto the column,  the lipids were 
eluted by using chloroform/methanol (2:1). Nonlipid material was eluted by using methanol/water 
(1:1).  The  lipids  and  nonlipid  eluates  were  then  dried  under  nitrogen.  Lipids  were  further 
fractionated on a silica gel column (Sigma Chemical Co., SI L-LC). Lipids were resuspended in 10 
ml of chloroform/methanol (9:1) and eluted by using subsequent 75 ml chloroform, acetone, and 
methanol steps. The various fractions were then blown dry under nitrogen and resuspended in 0.05 
M Tris-HC1 buffer (pH 8.3) and used for absorption studies. Thin-layer chromatography demon- 
strated that the chloroform eluate consisted of fatty acids, glycerides, and glycerol whereas the 
acetone phase contained the glycolipids and the methanol phase the phospholipids. 
METHOD II.  Membranes were resuspended in ethanol/ether (3:1) and stirred for 15 min at 4°C. 
The supernate was removed by filtration and the residue was extracted two more times, as above. 
The filtrates were then combined and blown dry under nitrogen. The residue and extracted lipids 
were treated as Method I and used for their ability to absorb HRA. 
Teichoic Acid Preparation.  Streptococcus mutans strain BHT wall teichoic acid was prepared by 
Vaught and Bleiweis (26),  group A  streptococcal cell wall teichoic acid was prepared by McCarty 
(27),  and erythrocytes sensitized with group A lipoteichoic acid were prepared by Ofek et al. (28). 
The above preparations were gifts from the individual investigators. 
Group A  streptococcal lipoteichoic acid was prepared according to the chloroform/methanol/ 
water  extraction  procedure  of Wicken  et  al.  (29)  by  using  protoplast  membrane  as  starting 
material. 
Cardiolipin (Sigma Chemical Co.) was deacylated according to the method of Wilkinson (30). 
Gel Filtration Chromatography.  Columns were calibrated by passing through them proteins of 
known molecular weight (bovine serum albumin, ovalbumin, and cytochrome C), and the distri- 
bution coefficient of each protein peak was calculated as described by Andrews (31). Blue dextran 
and  2~Na were  used  to  determine  void volume  and total  volume  of the  column,  respectively. 
Volumes were determined gravimetrically. Column fractions were tested for protein concentrations 
by the method of Lowry et al.  (32),  and radioactivity was determined in a  Packard model 3022 
gamma spectrometer.  (Packard Instrument Co., Inc., Downers Grove, Ill.) 
Preparation of Rabbit Antisera.  Inocula and inoculation schedules for antisera were prepared 
according to the method of van de Rijn and Bleiweis (33). New Zealand Red male rabbits were bled 
for preimmune  HRA controls.  Only  rabbits without HRA  present in their sera  were  used  for 
subsequent inoculation. 
Preparation  of Fluoresceinated  Goat Anti-Gamma  Globulin.  Serum  from  either  rabbits  or 
humans was collected and dialyzed (three times) against 10 vol of 0.02 M sodium phosphate buffer 
pH 7.0. The dialyzed serum was then loaded onto a column of DE 52 (Whatman Chemicals, Div. W 
& R Balston, Maidstene, Kent, England) (2.5 vol/vol serum) equilibrated with the above buffer. 
Tubes containing only gamma globulin as determined by cellulose acetate electrophoresis (34) 
were pooled and concentrated by using an Amicon stirred cell with a  XM 50 membrane (Amicon 
Corp., Scientific Sys. Div. Lexington, Mass.). Female goats (35-40 pound) were inoculated with 1.5 
mg purified gamma globulin in 1 ml incomplete Freund's adjuvant (Difco Laboratories Detroit, 
Mich.) into their back thigh muscles. Similar injections were administered 3 and 5 wk after the 
first inoculation. The goats were bled 1 wk after the final inoculation, and the gamma globulin 
fraction were  isolated  from  the  serum  as  outlined above.  The  isolated  goat  gamma  globulin 
fraction was next adjusted to a concentration of 10 mg/ml with 0.5 M sodium carbonate buffer pH 
9.5.  Fluorescein isothiocyanate (BBL, Cockeysville, Md.) was then added slowly with stirring at 
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under nitrogen. Tagged gamma globulin was separated from free fluorescein isothiocyanate by 
passing over a column of Sephadex G-25 equilibrated with 0.0125  M sodium phosphate (pH 5.7). 
The conjugate was then pooled and dialyzed against 0.01 M PBS pH 7.6. Finally, it was aliquoted 
and stored at -70°C until use. 
HRA Assay.  Sera were assayed for the presence of HRA by the indirect immunofluorescence 
staining technique of Zabriskie and Freimer (7) with the following modifications: the dessicated 4- 
/~m frozen normal heart sections were fixed in acetone for 1 rain followed by a 5-min wash in 0.01 M 
PBS pH 7.6.  The sections were permitted to air dry and then incubated with various dilutions of 
the test sera for 25 min at 23°C in a moist chamber. The sections were again washed for 5 min in 
PBS and allowed to air dry. The sections were then counterstained with the appropriate fluores- 
ceinated antisera and incubated for an additional 25  rain. The sections were finally washed in 
PBS, air dried, and a  cover slip applied by using a mixture of glycerol and PBS (6:4). The slides 
were analyzed by using a Zeiss Universal Ultraviolet microscope (Carl Zeiss, Inc., New York) with 
BG 12 and 440-~m filters. All slides were graded on a 0-4+ scale with 4+ representing the greatest 
intensity of staining. 
Absorption of  liRA.  5/~l of rheumatic sera which gave a 4+ staining at a dilution of 1:10 were 
added to a microfuge tube containing 45/~m of a dilution of the sample containing the CRA. The 
contents were mixed and allowed to incubate at 37°C for 2 h and then overnight at 4°C. Just before 
use, samples were centrifuged for 5 min in a  microfuge 152  (Beckman Instruments Inc., Cedar 
Grove,  N.  J.),  and the supernate was used in  the  HRA  assay.  Unabsorbed sera  which were 
incubated for the same periods of  time were used at a 4+ staining control. Normal sera were used 
as negative controls. All dilutions were in 0.01 M PBS (pH 7.6). 
Polyacrylamide Slab Gel Electrophoresis.  The purification of the CRA was followed by sodium 
dodecyl sulfate  polyacrylamide gradient  gel  electrophoresis (SDS-PAGGE)  by  the  method of 
Laemmli (35) by using a discontinuous Tris-HC1 buffer system. Electrophoresis was carried out on 
a  7-15% gradient slab polyacrylamide gel at 25 mA for 18 h  or on 14% polyacrylamide slab gels 
until the indicator dye just reached the bottom of the slab. 
Standards (bovine serum albumin, ovalbumin, carbonic anhydrase, and cytochrome C) were 
run on all gels for molecular weight determination. Samples and standards in 2% sodium dodecyl 
sulfate (SDS), 5% mercaptoethanol, and 10% glycerol were boiled (2-5 min) in a water bath before 
loading onto the gels. After electrophoresis, the gels were placed in a solution of 7% acetic acid and 
25% isopropanol for 10 min to remove any excess SDS. The process was repeated for two additional 
washes in this same solution. The gels were then stained by using 0.2%  Coomassie Blue in 7% 
acetic acid with 25% isopropanol on a  Gyrotory water bath shaker (model G76,  New Brunswick 
Scientific Co., New Brunswick, N. J.) for 2 h at 45°C. For destaining, the gels were placed in 7% 
acetic acid and 25% isopropanol and replaced on the shaker for an additional 2 h. Afterwards, the 
staining solution was removed and fresh destaining solution was added. The gels were permitted 
to sit in this solution until all the background stain was removed. 
Gels containing ~25I-labeled samples were run in a  similar manner except that the gels were 
dried according to the procedure of Maizel (36) and exposed to Kodak X-ray film (Eastman Kodak 
Co.,  Rochester,  N.  Y.)  (Blue  brand,  BB54)  to  determine their radiolabeled bands  by  radio- 
autography. 
Cellulose Acetate Electrophoresis.  Zone electrophoresis  of serum proteins was run according to 
the method of Osterland et al. (34). The acetate strips were then fixed with 20% sulfosalicylic acid 
and stained with 0.25% Coommassie Brilliant Blue R (Sigma Chemical Co.). 
Immunoelectrophoresis.  Immunoelectrophoresis was  performed by  a  previously  described 
method (33). Serum samples were electrophoresed  at 5 mA per slide for 45 rain at 4°C. Rabbit anti- 
human  serum  (Behring Diagnostics,  Woodbury,  N.  Y.)  was  then  added to  the  troughs  and 
incubated at 22°C for 24 h  and at 4°C for 72 h. 
Protein Determination.  All protein determinations were by the method of Lowry et al. (32) by 
using bovine serum albumin as  a  standard.  Whenever nonionic detergent was present in the 
protein solution, 4% SDS was added to the sodium carbonate solution to prevent precipitation of 
the nonionic detergent during the assay. 
Radioiodination  of Molecules and Binding Assays.  Gamma globulin preparations were la- 
beled with 125I by the method of Greenwood et al. (37) and unbound iodine was removed by column 
chromatography by using Sephadex G-50. Membranes (100 ~g) were incubated in the presence of 584  GROUP  A  STREPTOCOCCAL  ANTIGENS 
'25I-labeled HRA or normal gamma globulin (150,000  cpm). To  each tube was also added ~Na 
(20,000 cpm) as a volume marker in 1% bovine serum albumin (BSA). The tubes were continuously 
mixed for 2 h at 37°C and for 18 h at 4°C after which each tube was counted. The tubes were then 
centrifuged in  a  Microfuge  152  (Beckman  Instruments Inc.)  for 5  rain  and  an  aliquot  of the 
supernate removed. Each tube was then recounted, and the percentage bound was determined 
according to the procedure of Gotschlich et al.  (38). All samples were assayed in triplicate. 
Results 
Binding Competition Studies Between Rabbit and Human HRA.  Rabbits 
were immunized with membranes isolated from group A  type 6  streptococci. 
After the  immunization schedule,  the  rabbits'  sera  contained high titers of 
antibodies which bound the sarcolemma of human cardiac myofibers as deter- 
mined by the indirect immunofluorescent staining technique. 
Frozen sections of normal and rheumatic human heart tissue were prepared 
and layered with either undiluted immune rabbit sera or a dilution of ARF sera 
that gave a 4+ reaction. These sections were counterstained with either fluores- 
ceinated goat anti-human gamma globulin  (F1-GAH)  or fluoresceinated goat 
anti-rabbit gamma globulin (F1-GAR) as recorded in Table Ia. Neither counter- 
stain showed any nonspecific staining when placed alone on the respective heart 
sections. The undiluted rabbit serum exhibited a 4+ reaction while the human 
serum (diluted 1:10) demonstrated a  4+ reaction (homologous systems). 
When the heterologous system was tested;  namely, with undiluted rabbit 
serum incubated first with the section followed by the diluted ARF serum and 
then the anti-human counterstain, similar results were seen  (Table Ib).  The 
ARF serum still exhibited a 4 + staining, indicating that the rabbit HRA did not 
block its binding. As demonstrated in the table, the rabbit antibody was still 
present on the section at a high concentration. 
Due  to  the  possibility that  the  rabbit  antiserum did  not  contain  enough 
antibody molecules to cover all the sites on the tissue, the following experiments 
were performed. After the initial incubation of the rabbit serum, fresh rabbit 
anti-membrane  serum  was  incubated  with  the  heart  sections  for  a  second 
incubation period before the ARF serum and counterstain were added. Again, 
no competition for the same antigenic determinant was demonstrated (Table Ic). 
As a second control to determine whether sufficient antibody was present to 
bind all of the sites, the rabbit serum after the initial incubation period was 
transferred to a second, fresh heart section and incubated for 25 min. The section 
was then counterstained with F1-GAR and a 4+ staining reaction was observed, 
exactly the same as seen with the first section, indicating that there was an 
excess of antibody present in the serum. 
To further rule out the possibility that the rabbit antibody binds the same 
sites as the human antibody, all of  the above experiments were repeated at 4°C. 
At this temperature, the normal incubation times were doubled to achieve the 
same degree of staining. Again, similar results were observed. All of the above 
experiments were also done in the reverse order to see if the human antibody 
could competitively block the rabbit antibody. No inhibition of rabbit antibody 
by human serum was demonstrated. 
Purification of HRA from ARF Sera.  From the above experiments, it be- 
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Binding Competition  Studies between Rabbit and Human HRA 
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Immunofluorescent 
Counterstain  1st serum  2nd serum 
staining 
(a) 
F1-GAR  R*  -  4+ 
F1-GAR  ARF  -  0 
F1-GAH  R  -  0 
F1-GAH  ARF  -  4+ 
(b) 
F1-GAH  R  ARF  4+ 
F1-GAR  R  ARF  4+ 
(c) 
F1-GAR  R x 2  ARF  4+ 
F1-GAH  R x 2  ARF  4+ 
* R, rabbit serum. 
elicited  in  the  rabbit  by  group  A  streptococcal membrane.  To  monitor the 
isolation of the antigen from the group A streptococcus which cross-reacts with 
human myocardial tissue, experiments were devised to isolate the HRA from 
the sera of ARF patients. This was desirable since it is well known that human 
sera normally contain antibodies to other streptococcal constituents. 
Sera from patients with acute rheumatic fever were tested for the presence of 
HRA by the indirect immunofluorescent staining technique. Those sera which 
contained a titer of 3-4+ at a dilution of 1:10 were pooled (35 bleedings from 15 
patients). 
The pooled sera were dialyzed three times against 10 vol of 0.02  M  sodium 
phosphate  buffer pH  7.0.  The  sera  were  then  loaded  onto  a  DE-52  column 
(Whatman, Inc., Clifton, N. J.) pre-equilibrated with the above dialyzing buffer. 
The gamma globulin was eluted by using the equilibration buffer. A second step 
of 0.04 M buffer was added after the protein concentration had reached base line. 
Fractions were tested for the presence of HRA by the indirect immunofluores- 
cent staining technique. The fractions containing HRA were pooled and concen- 
trated by using an Amicon stirred cell (Amicon Corp., Scientific Sys. Div.) with 
a XM 50 membrane. Finally, sodium chloride was added back to a concentration 
of 0.15 M. 
To  1 vol of premoistened sarcolemmal sheaths  was  added 2  vol of column 
chromatographed HRA, and the mixture was allowed to incubate at 37°C for 2 h 
with gentle stirring. The sarcolemmal sheaths were then centrifuged at 28,000g 
for 10 min at 4°C. The supernate was saved for further analysis while the l~.llet 
was resuspended and washed four times with a mixture of 5% sucrose, 1% BSA, 
0.034 M  NaC1,  0.0025 M  phosphate, pH 6.8 at 4°C  according to the method of 
Edgington (39). Potassium iodide (2.5 M) was dissolved in PBS, and 10 vol of  this 
solution was rotated for 20 rain at 22°C with 1 vol of the washed sarcolemmal 
sheaths containing adsorbed HRA. The preparation was promptly centrifuged 
and filtered to remove the sarcolemmal sheaths, and the dissociated HRA was 
concentrated and equilibrated with PBS by ultra  filtration in an Amicon stirred 
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The optimal concentration of potassium iodide was determined as follows. An 
aliquot (20 ~g) of HRA was labeled with ~2~I and separated from free iodine by 
Sephadex G-50 chromatography. The labeled antibody was added to unlabeled 
antibody and the mixture absorbed to isolated sarcolemmal sheaths. After a 1-h 
incubation period, the sheaths were washed in cold buffer until the counts in the 
wash stabilized,  indicating the removal of unbound proteins.  Analysis of an 
aliquot of sarcolemmal sheaths by immunofluorescence demonstrated the pres- 
ence of HRA.  Aliquots of the washed sarcolemmal sheaths containing HRA 
were centrifuged and resuspended in PBS with increasing concentrations of po- 
tassium iodide and counted in a  gamma counter.  After a  20-min  incubation 
period, the sheaths were removed by centrifugation and filtration and the ex- 
tracts were counted. A  maximum recovery rate of 85% was reached at 2.5  M 
potassium iodide. This is in agreement with the work of Edgington (39) doing 
similar studies with erythrocyte membranes. A  second incubation of the sar- 
colemmal sheaths with 2.5 M potassium iodide released another 5% of the anti- 
body. 
Specificity  of the Isolated Antibody.  When layered on a  human heart sec- 
tion, the isolated HRA bound to the sarcolemmal sheath (Fig. 1 a). The specific- 
ity of the binding was confirmed since no staining was observed with brain, 
kidney, or liver tissues. The antibody bound only to heart and skeletal muscle 
sections. The only noticeable difference in the staining pattern of the purified 
antibody was that the intensity of staining to skeletal muscle was substantially 
decreased after the purification procedure. The isolated antibody also no longer 
bound to smooth muscle cells of the blood vessel walls. 
Purity and Activity  of the HRA.  Cellulose acetate electrophoresis demon- 
strated the presence of gamma globulin as well as contaminating BSA from the 
washing buffer. The BSA could easily be removed by rechromatographing the 
antibody on diethylaminoethyl (DEAE) cellulose. The cellulose acetate electro- 
phoresis did not demonstrate any other protein moiety with an electrophoretic 
mobility different from the  antibody. Immunoelectrophoresis of the  isolated 
antibody against goat anti-human serum demonstrated only a single precipitin 
arc in the region of gamma globulin. 
Finally, to determine the specificity and purity of HRA,  an aliquot of the 
purified HRA was  labeled with  12sI. After the free iodine was  removed, the 
antibody was incubated with sarcolemmal sheaths and 2~Na for 2 h at 37°C then 
at  4°C  overnight with  constant rotation.  The  tubes  were  then  counted and 
centrifuged at 13,000 g  for 5 min. An aliquot of the supernate was removed, and 
the tube was recounted. Calculations to determine the percent of radiolabeled 
antibody bound to the sarcolemmal sheaths were done according to Gotschlich et 
al. (38). Group D streptococcal membranes were added to a duplicate set of  tubes 
as a control. The results are tabulated in Table II. The purified HRA bound only 
to the  sarcolemmal sheaths,  indicating again the  specificity of the  reaction. 
Also, over 99% of the material was active antibody. To rule out the role of an Fc 
receptor on the sarcolemmal sheaths, normal gamma globulin controls were also 
run.  No  binding of the gamma globulin occurred to  either the  sarcolemmal 
sheaths or the group D membranes. 
Identification  of the  Classes  of Immunoglobulins  Present  in  HRA.  The I.  van de RIJN,  J.  B.  ZABRISKIE,  AND  M.  McCARTY  587 
FIG.  1.  Immunofluorescent staining of human myocardium with purified HRA isolated 
from ARF patients. (a) The antibody bound the sarcolemma of the cardiac myofibers. (b) 
This staining pattern was absent when the HRA was absorbed with purified CRA. 
TABLE II 
Specificity and Purity of liRA 
Average percent bound* 
HRA  Normal gamma 
globulin 
Sarcolemmal sheaths  99.4  0.4 
Group D streptococcal membranes  2.0  1.3 
* All tests were done in triplicate. 
purified HRA was layered onto human myocardial sections and counterstained 
with fluoresceinated heavy-chain-specific antibody. Only antibodies of the IgG 
class could be demonstrated. This purified HRA was then used to monitor the 
isolation and purification of the streptococcal CRA. 
Distribution  of CRA  in  the  Membranes  of Various  Serotypes  of Group A 
Streptococci.  Protoplast membranes were isolated from seven group A strepto- 
coccal  strains,  including six  different serotypes,  by  using  purified  group  C 
phage-associated lysin. Membranes from a  group D streptococcus served as a 
control. All seven group A  streptococcal membrane preparations were able to 
remove the HRA from acute rheumatic fever serum as demonstrated by loss of 
fluorescence, indicating the presence of the  antigen in the membranes of all 
types tested (Table III). The group D membrane preparation did not contain the 
cross-reactive  antigen.  These  results  were  confirmed by  12~I-labeled purified 
human HRA binding studies. Again, all seven group A streptococcal membrane 
preparations bound the purified HRA at levels of 97% or greater, whereas the 
group D membranes bound only 2%. None of the membrane preparations bound 
more than 3% of  the normal human gamma globulin, indicating that nonspecific 
binding through Fc receptors did not occur in any of the membrane prepara- 
tions. 
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TABLE III 
Presence of CRA in Membrane Preparations from Various Serotypes of 
Group A Streptococci 
Percent binding* 
Fluorescence* 




Unadsorbed  control  4 + 
$43/192/2 (type 6)  0  99  2 
D471 (type 6)  0  99  1 
T12/126 (type 12)  0  97  1 
B429 (type 14)  0  100  3 
85RP87 (type 18)  0  98  2 
D420 (type 41)  _+  99  0 
A918 (type 55)  1+  97  1 
A932 (group D)  4+  2  1 
* Membranes (100 ~g/ml) were used to bind '25I-labeled purified human HRA 
or normal human gamma globulin. 
$ Membranes (100/~g/ml) were used to absorb ARF serum. Slides were graded 
0-4+ with 4+ indicating  the highest intensity of fluorescence. 
membranes  from group  A  streptococcal  strain  S43/192/2  were  incubated  with 
various enzymes for a period of 1 h  at 37°C. The pellet and supernatant fractions 
were then  assayed for their  ability to remove HRAs from ARF patients'  sera. 
Proteolytic enzymes destroyed the  antigen  as demonstrated in Table IV.  Only 
low concentrations  of pepsin  (100  U/ml)  did  not  completely destroy the  CRA. 
Lipase  and  glycosidases  had  no  effect  on  the  antigen  nor  did  they  release 
antigens into the supernate.  To further rule out the possibility of a  glycoside as 
part of the immunodeterminant of the CRA, membranes were incubated with a 
mixture of at least 12 glycosidases at pH 5 and 6 for 18 h with constant mixing at 
37°C.  Again, there was no loss of activity.  Since glycosidases cannot,  at times, 
remove sugar residues  from protein  due  to  the  short  glycosidic  chain  length, 
membranes were also treated with 2% periodic acid (not shown) for I  h  at 37°C. 
Again, there was no loss of activity observed.  Even though the involvement of 
carbohydrates  cannot  be  excluded,  the  experimental  data  indicated  that  the 
antigen was a  protein. 
Since  lipid  extraction  of the  membrane  by  the  procedure  of  Folch  et  al. 
released  a  small  amount  of the  CRA  (Table  V),  the  various  membrane  lipids 
were  isolated.  The  antigen  was  located  in  the  nonlipid  fraction  and  was  de- 
stroyed when treated with proteolytic enzymes, giving further evidence that the 
CRA was a  protein. The purified lipid fractions from silica gel chromatography 
were devoid of the  antigen. 
Ethanol/ether extraction did not release any of the CRA yet did remove most 
of the  lipid.  Upon analysis of the  residue,  only 5% of the  antigen  was lost as 
compared to  10%  by using  the  Folch extraction  technique.  The  ethanol/ether 
extraction was therefore used as an initial step m  purification of this antigen. 
Since  various  investigators  (40,  26)  have  speculated  that  the  CRA  was  a 
teichoic or lipoteichoic acid, the following experiments were performed to deter- 
mine the involvement ofteichoic acid as a CRA. Teichoic acid preparations were I.  van de  RIJN,  J.  B.  ZABRISKIE,  AND  M.  McCARTY  589 
TABLE  IV 
Effect of Enzymes on Group A  Streptococcal Membranes Containing 
the CRA * 
U/ml 
Ability to absorb HRA 
Residual  Solubilized 
membranes  components 
Proteases 
Trypsin  100-1,000  I*  I 
Pepsin  100  A§  I 
1,000  I  I 
10,000  I  I 
Papain  10-40  I  I 
Lipase 
Phospholipase C  5-50  A  I 
Glycosidases 
a-glucosidase  5-100  A  I 
fl-glucosidase  1-25  A  I 
fl-galactosidase  10-1,000  A  I 
Mixed glycosidases  0.2%  A  I 
* Membranes (1 mg/ml) were incubated for 1 h at 37°C,  a~er which they were 
treated with enzyme inhibitors. 
$ Inactive. 
§ Active. 
TABLE  V 
Examination of Various Lipid Fractions from Group A  Streptococcal 
Membranes for the Presence of the CRA 
Fraction used for adsorption  Intensity of fluorescence* 
Unadsorbed control  4+ 
Streptococcal membrane  0 
Folch extract  3+ 
Calcium chloride treatment 
Upper layer  3 + 
Lower layer  4+ 
Sephadex chromatography 
Nonlipids 
Lipids  4+ 
Silica gel chromatography 
Glycerol fraction, fatty acids, glycerides  4+ 
Glycolipid fraction  4+ 
Phospholipid fraction  4+ 
Residue  0 
Ethanol/ether extract  4+ 
Residue  0 
* All slides were graded on a scale of 0-4+ with 4+ demonstrating the highest 
level of fluorescence. 
obtained from various investigators  (see  Materials and Methods) as well as 
isolated from group A streptococci in our laboratory. Neither the wall teichoic 
acid nor membrane lipoteichoic acid of the group A streptococcus could absorb 
HRAs  (Table  VI).  Erythrocytes were  sensitized  with  group  A  streptococcal 590  GROUP  A  STREPTOCOCCAL  ANTIGENS 
TABLE VI 
Adsorption of liRA from Acute Rheumatic Fever Patients' Sera  by 
Using Teichoic Acid Preparations 
Preparation  Intensity of fluorescence* 
Unadsorbed control 
Group A streptococcal membrane 
Group A streptococcal wall teichoic acid 
Group A streptococcal lipoteichoic acid 
Erythrocytes sensitized with group A streptococcal 
lipoteichoic acid 











* All slides were graded on a scale of 0-4+ with 4+ demonstrating the highest 
level of fluorescence. 
lipoteichoic acid to determine if insolubilized lipoteichoic acid was effective in 
removing HRA, again, the antibody was not removed. Also, a wall teichoic acid 
from S.  mutans  strain  BHT  which is  substituted with di-  and  trigalactosyl 
residues  had  no  effect on  the  removal  of HRA.  Cardiolipin  as  well  as  its 
deacylated derivative also did not remove HRA.  This data indicated that the 
teichoic and lipoteichoic acids were not part of the CRA. 
Purification of the CRA.  A frequently used method for demonstrating the 
complexity and diversity of membrane proteins in SDS-PAGGE.  Fig. 2 shows 
the  resolution  of the  total  membrane  proteins  of strain  $43/192/2  (type  6) 
electrophoresed  on  a  7-15%  polyacrylamide gradient  slab  and  stained  with 
Coomassie Blue. Under these conditions, a minimum of 60 polypeptides can be 
resolved, ranging from a minimum of approximately 10,000 daltons to two high 
molecular weight polypeptides which just enter the running gel under these 
conditions. Essentially the same polypeptide distribution can be obtained if 2- 
mercaptoethanol is omitted from the sample, indicating that there are few, if 
any, intermolecular disulfide bridges in the proteins of this membrane. 
Since the studies indicated that the CRA was a protein, protoplast membranes 
(1  g)  were delipidated by using the ethanol/ether technique. The organic sol- 
vents were removed by desiccation of the residue in vacuo. The residue (5 mg 
detergent/mg residue) was then treated with 4% Emulphogene BC 720  (a gift 
from GAF Corp., New York) in 0.01 M ammonium bicarbonate buffer (pH 8.3) 
for 3 h at room temperature with stirring. Particulate material was removed by 
centrifugation at 125,000 g  for 2 h  at 4°C. Pellets were re-extracted until all of 
the  CRA  was  solubilized  (four  to  six  times)  as  determined  by  adsorption. 
Extracts  were  pooled  and  dialyzed against  DEAE-cellulose  chromatography 
starting buffer at 4°C overnight. 
An aliquot of  the extracted material was removed, and the protein was labeled 
with ~5I  by the  chloramine T  method of Greenwood et  al.  (37). The labeled 
material, free of unbound iodine, was added back to the dialyzed extract. The 
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FIG.  2.  SDS-PAGGE  of  SDS-solubilized  group  A  streptococcal  protoplast  membrane 
(strain $43/192/2).  Sample (150 ~g) was loaded, electrophoresed, and stained as outlined in 
Materials and Methods. A minimum of 60 polypeptides can be discerned from the gel (MW, 
molecular weight). 
which was pre-equilibrated with 0.01 M ammonium bicarbonate buffer (pH 8.3). 
The column was then washed with 5 vol of starting buffer. The antigen was 
eluted by using a linear gradient of 300 ml of ammonium bicarbonate (0.01-0.25 
M, pH 8.3). A final 1 M ammonium bicarbonate step (pH 7.7) was used to elute 
the remainder of the protein bound to the column. 
Material in the fallthrough, 1 M ammonium bicarbonate step, and the frac- 
tions from the linear gradient were assayed for 1~I and CRA. The CRA eluted at 
an ammonium bicarbonate concentration of  0.05 M (Fig. 3) and was not found in 
any of the other fractions. SDS-PAGE (14%) demonstrated that these fractions 
contained six polypeptides (mol wt 20-35,000)  and some lower molecular weight 
protein staining material. CRA was purified 65-fold through this step with a 
yield of 79%  (see Table VII). 
The fractions containing the antigen were pooled and concentrated by using 
an Amicon stirred cell (Amicon Corp.) with a UM 10 membrane and chromato- 
graphed on a  reverse flow Sephadex G150 column (1.5  ×  90 cm) equilibrated 
with 0.2 M ammonium bicarbonate (pH 7.7) and eluted at a flow rate of 10 ml/h. 
Fractions (1.5 ml) were collected and assayed for their ability to absorb HRA. 
CRA eluted in fractions 40-55  as shown in Fig. 4.  Upon analysis, CRA were 
shown to be purified 120-fold with a 42% yield (Table VII). The active fractions 592  GROUP  A  STREPTOCOCCAL  ANTIGENS 
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FIa.  3.  Elution profile from DEAE-cellulose chromatography of nonionic detergent solu- 
bilized streptococcal membrane (701 rag). CRA was eluted by using a linear gradient of 300 
ml of ammonium bicarbonate (0.01-0.25 M, pH 8.3).  3-ml fractions were collected at a flow 
rate of 25 ml/h and monitored for ~25I-labeled protein, ionic strength, and their ability to 
adsorb HRA. The CRA eluted at an ionic strength of 0.05  M. 
TABLE VII 
Purification of CRA 
Fraction  Protein  Activity*  Specific activity  Purification  Yield 
mg  U  U/mg protein  % 
Protoplast membrane  740  50,000  67.6  -  100 
Ethanol/ether residue  701  45,565  65  -  91 
DEAE-cellulose chroma-  8.99  39,500  4394  65  79 
tography 
Sephadex  G150  chroma-  2.6  21,091  8112  120  42 
tography 
* 1 U of  activity  is  equal  to  the minimum  amount of  CRA needed  to  absorb HRA  from ARF sera (50 
/~l)  as determined by loss  of  fluorescence from 4+ to 0. 
were pooled, concentrated, and analyzed by sodium dodecyl sulfate polyacryl- 
amide  gel  electrophoresis  (SDS-PAGE)  radioautography  (Fig.  5).  Only  four 
closely-spaced polypeptides could be demonstrated in the pooled, active Sepha- 
dex G150 fraction. Analysis of the mol wt of these peptides demonstrated that 
they were 32,000,  28,000,  26,000,  and 22,000 daltons, respectively (Fig. 5).  Our 
final product, then, is composed of four polypeptides which comprise less than 
0.6%  of the dry weight of the starting material.  Finally, the 120-fold  purified 
CRA was incubated with purified HRA to assay for the absorption of HRA. As 
can be seen by the complete loss of immunofluorescence (Fig.  1 b), the purified 
CRA absorbed the HRA. This is in comparison to Fig. 1 a in which the HRA was 
not absorbed. 
Discussion 
Our evidence suggests that the antibody induced in rabbits by streptococcal 
membranes is different from that found in ARF patients. The data suggest that 
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FIG.  4.  Elution profile of CRA from Sephadex G150, equilibrated, and eluted with 0.2 M 
ammonium bicarbonate pH 7.7.  A  total of 8.99 mg of active pooled fractions from DEAE- 
cellulose chromatography was applied to the column at an upward flow rate of 10 ml/h. 1.4- 
ml fractions were collected and analyzed for ~SI-labeled protein and their ability to absorb 
HRA. Intensity is the amount of fluorescence remaining after absorption of HRA with the 
appropriate fraction. 
the same or different molecules. Support for these different antigenic determi- 
nants comes from our observations that the intensity of staining by the rheu- 
matic serum is not reduced after preincubation with rabbit anti-heart antibody. 
The converse is also true; that is, the rheumatic serum will not block the binding 
of the rabbit antibody to the sarcolemmal sheath.  Yet absolute proof of this 
statement must await isolation and purification of the sarcolemmal antigens 
involved. 
Since our interest lay primarily in the isolation of CRA responsible for human 
HRA,  efforts were directed towards the isolation and characterization of the 
human antibody. There were two main reasons for pursuing this course. First, 
since ARF sera contain high titer antibodies to many other streptococcal compo- 
nents,  the isolation of the heart-reactive antigen is necessary to monitor the 
purification of the CRA of the group A streptococcus. Secondly, since the rabbit 
antibody appears to be  directed toward a  different antigenic specificity, only 
human HRA can be used for this purpose. 
The  purified  HRA  did  not  lose  any  of its  specificity by  this  purification 
procedure (Table II). Zabriskie et al.  (5) demonstrated that 10% of the patients 
with ARF contained in their sera an antibody which also bound to the smooth 
muscle cells of the blood vessel walls. It should be pointed out, however, that 
antibody to smooth muscle cells of the blood vessel walls and skeletal muscle 
were not efficiently absorbed with our sarcolemmal sheath preparations. 
The potassium iodide technique released the antibody from the sarcolemmal 
sheaths in a native state without the apparent release of sarcolemmal antigen. 
Potassium iodide acts as a  chaotropic ion by modifying the hydrogen bonding 
and can therefore disrupt intermolecular interactions (41, 42). Antibody isolated 
in this manner has remained stable over a period of 2 yr. 
The  work  of Kaplan  and  Meyeserian  (2)  and  Zabriskie  and  Freimer  (7) 
demonstrated that there was an antigen present in the group A streptococcus 594  GROUP  A  STREPTOCOCCAL  ANTIGENS 
Fla.  5.  Autoradiograph of 120-fold purified CRA. A sample of  the purified CRA was loaded 
onto a 14% SDS-PAGE and run as outlined in Materials and Methods. Four polypeptides of 
32,000,  28,000,  26,000,  and 22,000 daltons, respectively, were resolved. 
which  was  similar  to  an  antigen  found  on  the  sarcolemma  of the  cardiac 
myofiber. These investigators were able to extract the antigens from the strepto- 
coccal membrane or wall by using either dilute hydrochloric acid or pepsin. This 
type of preparation was able to remove HRA from the serum of ARF patients. 
Neither group of investigators characterized the  antigen to any degree other 
than to hypothesize that it was a protein since it was trypsin sensitive and that, I.  van de  RIJN,  J.  B.  ZABRISKIE~  AND  M.  McCARTY  595 
in the case of Kaplan (3), the antigen was associated with, but not identical to, 
the M protein moiety. 
Other investigators also have defined immunological systems associated with 
M protein (43, 44).  Beachey et al.  (40) defined two non type-specific M  (NTSM) 
associated antigens.  One was demonstrated to be a  teichoic acid found associ- 
ated with the cell wall and membrane while the other still remains unidentified. 
Pachman and Fox (45) and Wittner and Fox (46) also demonstrated that teichoic 
acid was associated with isolated M protein preparations. 
A second NTSM antigen was also defined by complement fixation by Widdow- 
son et al. (44). Protoplast membranes were shown to absorb out these antibodies, 
and  they  are  present  in  high  titers  in  ARF  patients'  sera.  Other  than  this 
antigen  being  sensitive to proteolytic enzymes  and  found associated to  some 
degree with  M  protein,  the  antigen  was undefined.  The relationship  of these 
complement-fixing  antibodies to HRAs has not been thoroughly investigated. 
Finally,  Vosti (47) isolated a  NTSM antigen  from type 12 whole cells and cell 
walls. Again,  its relation to the tissue CRA was not assessed. 
In our studies, we have been able to demonstrate that all group A streptococ- 
cal protoplast membranes which were tested bind purified human HRA at levels 
of 97% or greater. Experiments devised to demonstrate that this binding was not 
through Fc receptors on the membrane indicated that the binding was specific. 
Of all the reagents used to determine the chemical nature of the CRA, only 
proteolytic enzymes could destroy the activity.  Earlier work by Zabriskie and 
Freimer  (7)  had  demonstrated  that  the  antigen  could be extracted  by using 
pepsin.  Our data indicate that the action of pepsin on the antigen is somewhat 
limited compared to other proteolytic enzymes but that once the CRA is released 
from the protoplast membrane,  it is easily degraded by the enzyme. Glycosides 
could  not  be  detected  in  the  antigen  preparations.  In  addition,  none  of the 
glycosidases tested were able to destroy CRA, indicating that  glycosides were 
not part of the immunodeterminant.  Upon analysis of the lipid fraction, antigen 
was located in the nonlipid part which was destroyed when treated with proteo- 
lytic enzymes.  It was later determined that this antigen was identical to that 
released by using nonionic detergent and that the lipid extraction released only 
a  minor  amount  of antigen.  Finally,  our evidence indicates  that  the  CRA is 
indeed not teichoic acid.  None of the streptococcal teichoic acids or cardiolipin 
could remove HRA. It still remains to be determined whether the antigen is a 
protein associated with the lipoteichoic acid which is removed from this moiety 
upon further purification. 
SDS-PAGE  analysis  demonstrated  that  the  group  A  streptococcal  mem- 
brane  was complex in relation  to its protein composition.  Of interest  was the 
finding that there are very few, if any, intermolecular disulfide bridges in the 
proteins of this membrane, a finding which has also been demonstrated in other 
prokaryotic membranes.  Another type 6 membrane  from which CRA was iso- 
lated  (strain  D471)  contained  a  very similar polypeptide pattern and had only 
minor  qualitative  and  quantitative  changes when compared to the  $43  mem- 
brane used in this study. 
Extraction  of the  streptococcal membrane  with nonionic  detergent released 
20-30  polypeptides.  It  was  necessary to  extract  membranes  several  times  to 596  GROUP  A  STREPTOCOCCAL  ANTIGENS 
remove all of the CRA.  Even though the earlier extracts contained different 
polypeptides than later ones, the antigen was present in all extracts so that we 
could not disregard particular ones during the extraction procedure. The final 
preparation of the CRA  was purifed 120-fold  with  a  yield of 42%. On  SDS- 
PAGE, only four polypeptides were demonstrated by radioautography with mol 
wt of 22,000, 26,000, 28,000, and 32,000 daltons. Attempts to separate these four 
polypeptides by isoelectric focusing, affinity chromatography and other forms of 
ion exchange chromatography have been unsuccessful to date. Because of this, 
we have been unable to determine the exact location of  the immunodeterminant 
on one or more of these molecules. It is also possible that the immunodetermi- 
nant is made up of  two or more adjacent molecules. Work is in progress to isolate 
the individual polypeptides to determine which molecule or molecules contain 
the active determinant. 
Summary 
Heart-reactive antibody (HRA) appears in the sera of experimental animals 
inoculated with group A streptococci as well as patients with acute rheumatic 
fever. Adsorption of either serum with group A streptococcal membranes will 
remove the HRA. Blocking experiments between these two types of HRAs have 
demonstrated that the antibodies are directed towards different antigenic deter- 
minants on either the same or different molecules. 
To  isolate  and  purify the  antigen  from the  group  A  streptococcus  cross- 
reactive with sarcolemmal sheaths of cardiac myofibers, it became necessary to 
purify the HRA from rheumatic fever patients' sera. Isolated gamma globulin 
containing all of the HRA was adsorbed onto human sarcolemmal sheaths. The 
specific HRA was released by using potassium iodide. Over 99% of the purified 
HRA was shown to bind the sarcolemmal sheath whereas less than 1% of the 
antibody would bind nonspecifically to other material. 
Preparations of group A streptococcal membrane will bind HRA purified from 
the  sera  of acute rheumatic patients  at  levels of 97%  or greater.  The  cross- 
reactive  antigen  solubilized  by  nonionic  detergent  was  purified  120-fold  by 
column chromatography. On sodium dodecyl sulfate polyacrylamide electropho- 
resis, the antigen was demonstrated to be composed of four polypeptides with 
mol wt of 32,000,  28,000,  26,000,  and 22,000 daltons, respectively. Only proteo- 
lytic enzymes could destroy the antigenic determinant whereas glycosidases and 
lipases had no effect. The purified antigen blocked the binding of purified HRA 
to normal human heart sections. 
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